Berlin, Germany, December 30, 2022, 6:00 p.m. CET – TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of new therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces today today the convening of an extraordinary general meeting of shareholders of the company (EGM) on January 30, 2023, at 1:30 p.m. CET, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, The Netherlands.
This EGM is organized in order to vote on the proposal to reduce the nominal value per share and to increase the authorized share capital.
To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected]